May 27th, 2021 | 10:13 CEST
CureVac, NSJ Gold, Steinhoff - New opportunities every day
Following a performance of over 15% since the start of the year, the DAX seems to be running out of steam around the 15,500 mark. At least a short correction would be more than due here and only healthy to tackle the next barriers to the top. Gold was able to break through the USD 1,900 mark for the first time this year. It should now be a done deal that the correction that has been underway since August has come to an end. The general conditions of rising inflation fears and the further loose monetary policy of the central banks should soon help the precious yellow metal to new highs.
time to read: 3 minutes | Author: Stefan Feulner
ISIN: NL0015436031 , CA62973P1071 , NL0011375019
Table of contents:
Author
Stefan Feulner
The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.
Tag cloud
Shares cloud
NSJ Gold - Best conditions
Gold is shining again. With the jump above the USD 1,900 mark, the precious metal is trending at its highest level since the beginning of January. After the high in August at USD 2,069.70, the price corrected until the end of April and completed the consolidation formation with a double bottom at USD 1,680. After breaking through the vertical resistance area at USD 1,880, the test of the USD 1,920 mark should now be tackled. Gold is getting a tailwind from the inflation fears as mentioned above. While the central banks continue to play down the price increases as temporary, inflation could escalate further due to the increased commodities. For this reason, the price is likely to significantly outperform the 2020 highs before the end of the year.
Of course, there are always corrections in new uptrends, sometimes stronger, but these should be used successively to increase the portfolio holdings with gold and silver. In addition to purchasing physical precious metals, the entry into fundamentally favorable gold and silver mining shares offers itself. In addition to the established gold producers, one should also look at shares of gold mining explorers. The young Company NSJ Gold stands out in particular, as their asset is in a prime location. The Canadians have secured an option to acquire a 100% stake in the Golden Hills Project in Arizona, which hosts highly prospective gold and copper deposits along the prolific Walker Lane Gold Trend.
High-grade copper and gold discoveries were made in this area as early as the mid-20th century. In the immediate vicinity is Arizona Metals' Kay Mine and Northern Vertex Mining's Moss Mine. Northern Vertex Mining has a market capitalization of more than CAD 120 million. The current Vice President of Exploration of NSJ Gold, Richard Kern, was responsible for developing the Moss Mine in the late 1990s. The property consists of seven patented claims and 114 unpatented mining claims, covering 29.6 km². The market value of NSJ Gold is currently only EUR 3.30 million. Should the nature of Golden Hills be anywhere near as high grade as its neighbors, there is enormous upside potential for the stock.
CureVac - When will the starting signal be given?
The figures for the first quarter of 2021 play a minor role at the vaccine manufacturer CureVac. According to the report, sales increased from EUR 3.1 million to EUR 10 million. The quarterly loss increased from EUR 23 million to EUR 116 million due to the expected high expenses in research and development. The reassuring cash cushion of EUR 1.5 billion is to be invested primarily in second-generation vaccine candidates. The Tübingen-based Company is on the home stretch with its first vaccine, CVnCoV, which is being developed with German pharmaceutical giant Bayer.
"With the support of our partner Bayer, we are moving CVnCoV forward and expect data from the pivotal phase 2b/3 trial in the second quarter. These will enable us to finalize the rolling approval process with the European Medicines Agency (EMA)," said CureVac CEO Franz-Werner Haas.
According to management, clinical trials with the new Covid-19 vaccine CV2CoV are expected to begin as early as the third quarter, according to management, in conjunction with GlaxoSmithKline. Chart-wise, the hurdle at EUR 95 is up for grabs, which the stock failed to clear at its last attempt. A breakthrough, which could be tangent with positive news in connection with the approval process, CureVac should make another attempt to overcome the all-time high at EUR 125.44.
Steinhoff International - Successful stock market debut
An important day for all Steinhoff shareholders. Even though there is still a high mountain of debt to work off, the successful stock market debut of the subsidiary Pepco is a step in the right direction. The issue price of the subsidiary, which operates more than 3,200 stores in 16 countries, was set at PLN 40, at the lower end of the price range between PLN 38 and PLN 46. The high in the course of trading yesterday was PLN 44.40 on the Warsaw Stock Exchange. Accordingly, the stock market value of the holding company, which is registered in the Netherlands, is currently just under EUR 5.6 billion. Steinhoff issued a total of 115.5 million shares, which means that the German-South African group raised around EUR 1 billion from the successful IPO. Steinhoff also continues to hold just under 79% of the shares.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.
The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.
